Skip to main content

Table 1 Published Susceptibility for HIV-1 Isolates with a Single NNRTI-Associated Drug Resistance Mutation (DRM) Ordered by Frequency in the ART-Naïve Dataseta

From: Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance

NNRTI DRMa

Number of sequences

Fold-reduced susceptibilityc median #tests

V106I

1137

 < 3.03

K103N

817

 < 3.09

V108I

158

 < 3.03

G190A

123

 < 3.05

Y181C

102

 < 3.07

A98G

91

 < 3.03

K101E

76

 < 3.06

E138K

49

 < 3.010

H221Y

45

 < 3.02

Y188L*

40

1068

V106M

27

3.41

G190E

17

181

G190Sc

11

3.06

V106A*

8

9.63

P225H

8

 < 3.02

F227L*

8

 < 3.02

Y188C

6

 < 3.01

Y318F*

5

112

Y181V

4

5.12

Y188H

3

 < 3.03

L100I

2

 < 3.03

  1. aThe table includes phenotypic susceptibility data published by the Merck Research Laboratory
  2. bSusceptibility data were not available for 12 mutations including two canonical doravirine DRMs, F227C and M230L that occurred in five sequences and ten additional NNRTI DRMs, L100V, K101P, V179F, Y181I, G190Q, F227I/V, M230I, L234I and P236L, which occurred in 46 sequences. Mutations followed by an asterisk are canonical doravirine-resistance mutations
  3. cThe median fold-reduction in the Monogram single mutation database study was < 3.0 for G190S
Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us